{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-024720","form_type":"8-K","ticker":"WINT","cik":"0000946486","company_name":"WINDTREE THERAPEUTICS INC /DE/","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.752258+00:00","generated_at":"2026-05-17T21:17:11.089712+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Windtree reports positive istaroxime interim data in SCAI Stage C cardiogenic shock; plans global Phase 3","bullets":["Interim analysis of first 20 patients in SEISMiC C Phase 2 study: no new safety signals, hemodynamic improvements consistent with prior trials.","Istaroxime was added to existing inotropes/vasopressors; no excess arrhythmias observed despite greater illness severity.","Company cites data as instrumental for moving istaroxime to a global Phase 3 program in heart failure and cardiogenic shock."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-024720","json":"https://secwatch.observer/filing/0001437749-25-024720.json","markdown":"https://secwatch.observer/filing/0001437749-25-024720.md","text":"https://secwatch.observer/filing/0001437749-25-024720.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946486/000143774925024720/0001437749-25-024720-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946486/000143774925024720/wint20250805_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:17:11.089712+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}